Tenax Therapeutics Inc.

(TENX) Trade

By |

Profile

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com.

Contact Information

Website: www.tenaxthera.com
Email: jesse@sternir.com
Main Phone: +1 919 855-2100
Address: ONE Copley Parkway
Address 2: Suite 490
State: NC
City / Town: Morrisville
Country: US
Postal Code: 27560

Issuer Information

Exchange: NSC
CEO: Anthony A. DiTonno
Employees: 10
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)(541714)

Equities News

Profile

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com.

Contact Information

Website: www.tenaxthera.com
Email: jesse@sternir.com
Main Phone: +1 919 855-2100
Address: ONE Copley Parkway
Address 2: Suite 490
State: NC
City / Town: Morrisville
Country: US
Postal Code: 27560

Issuer Information

Exchange: NSC
CEO: Anthony A. DiTonno
Employees: 10
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)(541714)

Equities News

$ 1.18 $ -0.03 (-2.48%)
Last Price 1.18 Change $ -0.03 Change % -2.48 Tick N/A
Bid 1.17 Bid Size 700.00 Ask 1.28 Ask Size 200.00
Open 1.20 High 1.22 Low 1.17 Prev Close 1.21
Last Trade Volume 64,048 52 Wk Hi 2.69 52 Wk Low 0.25
Market Cap 14.9 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 12,619,369.00 EPS (TTM) -1.36 PE Ratio N/A Exchange NCM
  Last 3 Mo Last 12 Mo
Number of Insider Trades 1 6
Number of Buys 1 5
Number of Sells 0 1
Net Activity 6425 6577
Last 10 Buys Shares
Blanck R Ronald 1,000
Blanck R Ronald 1,000
Gerald T. Proehl 1,000
Gerald T. Proehl 1,000
James Mitchum 1,000
James Mitchum 1,000
Blanck R Ronald 1,000
Blanck R Ronald 1,000
Blanck R Ronald 1,000
Anthony A. DiTonno 1,000
Last 10 Sell Shares
Blanck R Ronald 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 41 41 41 41
Low Target Price Estimate 15 15 15 15
Mean Target Price Estimate 28 28 28 28
Standard Deviation 18.38 18.38 18.38 18.38
Date of Most Recent Estimate 06/03/18 05/29/18 04/11/18 06/03/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 1 1 1 1
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1 1 1 1